COVID-19 Access Industrial Policy Regulatory and legal framework Falsified medicines Environment Antimicrobial resistance Medicine shortages

 

COVID-19

• Watch Webinar that was held on July 9 2020
• Lessons learned from Covid-19 – Policy Paper last updated in May 2022
• Preparing for a potential second COVID-19 wave. Joint statement by Medicines for Europe and EFPIA with Kearney
• COVID-19 “Round 2” – Findings & way forward (Kearney)
• COVID19 Second wave pandemic preparedness: procurement principles.

To ensure manufacturing and supplying, day and night our members are continuously assessing portfolios, forecast, manufacture and supply to best meet the increasing demands posed by COVID19.

We are working closely with government and policy makers both at EU and national level so that we do all we can to maintain the development, production, supply and distribution of high-quality medicines during the pandemic

 

Key documents

SUPPLY

• Letter: Impact of COVID-19 on active ingredient and medicines manufacturing and supplies in Europe – 18 February 2020
• Letter: Coordination with industry on potential impact of Covid-19 on medicines manufacturing and supplies in Europe – 10 March 2020
• Statement: Critical to keep the supply chain of essential medicines manufacturing operating at full capacity – 18 March 2020
• Statement: Medicines for Europe update regarding medicines production and supply related to COVID-19 – 18 March 2020
• Letter: Heads of state and government should prioritise medicines in covid-19 actions – 26 March 2020
• Statement: Prioritise Medicines in COVID19 Actions – 26 March 2020
• Statement: Supply of essential ICU medicines – 02 April 2020
• Medicines for Europe welcomes European Commission decision to enable secure supply of hospital medicines  – 08 April 2020
• Letter to EU Trade Ministers. European Industry trade and supply chain needs to respond to Covid-19 – 10 April 2020
• Call for tenders SANTE/2020/C3/29 for the supply of medicinal products used for intensive care patients subject to the novel coronavirus (COVID-19) disease – policy and technical concerns – 25 June 2020

TREATMENT

• Statement: EMA clarifies no scientific evidence to deter use of ibuprofen to manage coronavirus symptoms – 18 March 2020

TRANSPORT

• Statement: Medicines for Europe Urgent requests to interior & Transport ministries regarding medicines production and supply. – 14 March 2020
• Statement: Air freight of critical medicines & Supplies – 21 March 2020

REGULATORY

• Statement: Digital transformation of healthcare – 26 March 2020
• EMA Questions and answers on regulatory expectations for medicinal products for human use during the COVID-19 pandemic

WORK FORCE

• Guidance – Best practice guidance on how to protect workers in relation to Covid-19 – 20 March 2020
• Guidance – Best practice guidance truck drivers – 26 March 2020
• European Commission guidelines: Free movement of workers during COVID-19 outbreak – 30 March 2020

[1] The Parliament Magazine. 2015. Available at:- https://www.theparliamentmagazine.eu/articles/opinion/many-patients-europe-have-limited-or-no-access-treatment

[2] Eurostat Population Statistics

[3] OECD, Fiscal Sustainability of Health Systems: Bridging Health and Finance Perspectives. 2015.

[4] SFK (Foundation for Pharmaceutical Statistics), Pharmaceutisch Weekblad. 2014.

[5] APM Health 2015. Available at: http://www.apmhealtheurope.com/home.php.

[6] QuintilesIMS Health. An International Comparison of Best Practice Approaches to Drug Shortages. 2015.